Citations (112)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (25)
Alessandro P. Delitala, Giuseppe Delitala, Paolo Sioni & Giuseppe Fanciulli. (2017) Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future. Current Medical Research and Opinion 33:11, pages 1985-1993.
Read now
Read now
Vasilios G. Athyros & Anthony S. Wierzbicki. (2014) Statin–fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low. Current Medical Research and Opinion 30:1, pages 57-58.
Read now
Read now
Michel Farnier. (2012) Pravastatin and fenofibrate in combination (Pravafenix®) for the treatment of high-risk patients with mixed hyperlipidemia. Expert Review of Cardiovascular Therapy 10:5, pages 565-575.
Read now
Read now
Anthony S Wierzbicki, Timothy C Hardman & Adie Viljoen. (2012) Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. Expert Opinion on Investigational Drugs 21:5, pages 667-676.
Read now
Read now
Vasilios G. Athyros, Konstantinos Tziomalos, Asterios Karagiannis & Dimitri P. Mikhailidis. (2010) Statin-fibrate combination for mixed dyslipidaemia: a limited option?. Current Medical Research and Opinion 26:9, pages 2137-2140.
Read now
Read now
Anthony S. Wierzbicki, Jonathan Morrell, Deborah Hemsley, Zofia McMahon, Martin A. Crook & Richard Wray. (2010) The effect of fibrate–statin combination therapy on cardiovascular events: a retrospective cohort analysis. Current Medical Research and Opinion 26:9, pages 2141-2146.
Read now
Read now
Giuseppe Derosa, Pamela Maffioli, Sibilla A. T. Salvadeo, Ilaria Ferrari, Alessia Gravina, Roberto Mereu, Ilaria Palumbo, Angela D'angelo & Arrigo F. G. Cicero. (2009) Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Current Medical Research and Opinion 25:8, pages 1973-1983.
Read now
Read now
Michel Farnier. (2008) Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vascular Health and Risk Management 4:5, pages 991-1000.
Read now
Read now
Konstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis & Dimitri P Mikhailidis. (2007) Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opinion on Therapeutic Targets 11:9, pages 1143-1160.
Read now
Read now
Manfredi Rizzo & Kaspar Berneis. (2007) The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Current Medical Research and Opinion 23:5, pages 1103-1111.
Read now
Read now
Irene F Gazi, Vasilis Tsimihodimos, Alexandros D Tselepis, Moses Elisaf & Dimitri P Mikhailidis. (2007) Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opinion on Biological Therapy 7:1, pages 53-72.
Read now
Read now
Anthony Wierzbicki. (2006) Future approaches to reducing low-density lipoprotein cholesterol. Future Lipidology 1:4, pages 463-476.
Read now
Read now
Stella S. Daskalopoulou & Dimitri P. Mikhailidis. (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current Medical Research and Opinion 22:3, pages 511-528.
Read now
Read now
Ranjababu Kulasegaram, Barry S. Peters & Anthony S. Wierzbicki. (2005) Dyslipidaemia and cardiovascular risk in HIV infection. Current Medical Research and Opinion 21:11, pages 1717-1725.
Read now
Read now
Mark Y Chan & Chi Hang Lee. (2005) Fluvastatin: efficacy and safety in reducing cardiac events. Expert Opinion on Pharmacotherapy 6:11, pages 1883-1895.
Read now
Read now
D. P. Mikhailidis, A. S. Wierzbicki, S. S. Daskalopoulou, N. Al-Saady, H. Griffiths, G. Hamilton, D. Monkman, V. Patel, J. Pittard & M. Schachter. (2005) The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Current Medical Research and Opinion 21:6, pages 959-969.
Read now
Read now
James Shepherd, John Betteridge & Luc Van Gaal. (2005) Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Current Medical Research and Opinion 21:5, pages 665-682.
Read now
Read now
Evagelos N. Liberopoulos, Stella S. Daskalopoulou, Dimitri P. Mikhailidis, Anthony S. Wierzbicki & Moses S. Elisaf. (2005) A review of the lipid-related effects of fluvastatin. Current Medical Research and Opinion 21:2, pages 231-243.
Read now
Read now
Anthony S Wierzbicki. (2004) Lipid-lowering therapies in development. Expert Opinion on Investigational Drugs 13:11, pages 1405-1418.
Read now
Read now
M. John Chapman, Gerd Assmann, Jean-Charles Fruchart, James Shepherd & Cesare Sirtori. (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*. Current Medical Research and Opinion 20:8, pages 1253-1268.
Read now
Read now
Teddy Kosoglou, Paul Statkevich, Bo Yang, Ramachandran Suresh, Yali Zhu, Tanya Boutros, Stephen E. Maxwell, Renger Tiessen & David L. Cutler. (2004) Pharmacodynamic interaction between ezetimibe and rosuvastatin. Current Medical Research and Opinion 20:8, pages 1185-1195.
Read now
Read now
Teddy Kosoglou, Paul Statkevich, Jean-Charles Fruchart, Laura J. C. Pember, Larisa Reyderman, David L. Cutler, Michel Guillaume, Stephen E. Maxwell & Enrico P. Veltri. (2004) Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*. Current Medical Research and Opinion 20:8, pages 1197-1207.
Read now
Read now
Kohji Shirai. (2004) Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Current Medical Research and Opinion 20:3, pages 295-304.
Read now
Read now
The UK HDL-C Consensus Group. (2004) Role of fibrates in reducing coronary risk: a UK Consensus. Current Medical Research and Opinion 20:2, pages 241-247.
Read now
Read now
Stavroula Tsiara, Moses Elisaf & Dimitri P. Mikhailidis. (2003) Early vascular benefits of statin therapy. Current Medical Research and Opinion 19:6, pages 540-556.
Read now
Read now
Articles from other publishers (87)
Leila Etemad, Zahra Salmasi, Seyedeh Alia Moosavian Kalat, Mohammad Moshiri, Javad Zamanian, Prashant Kesharwani & Amirhossein Sahebkar. (2023) An overview on nanoplatforms for statins delivery: Perspectives for safe and effective therapy. Environmental Research 234, pages 116572.
Crossref
Crossref
Jia Xu, Yang Wei, Yi Huang & Xinlin Wei. (2023) Regulatory Effects and Molecular Mechanisms of Tea and Its Active Compounds on Nonalcoholic Fatty Liver Disease. Journal of Agricultural and Food Chemistry 71:7, pages 3103-3124.
Crossref
Crossref
Lin-Zi Li, Hui-Ying Wang, Jia-Hui Huang, Kun Liu, Xiao-Jie Feng, Xi-Ming Wang, Li-Jie Zhu, Xing-Lishang He, Xiang Zheng, Hai-Long Li, Ying-Jie Dong, Bo Li, Han-Song Wu, Ning-Hua Jiang, Gui-Yuan Lv & Su-Hong Chen. (2022) The Mechanism of Dendrobium officinale as a Treatment for Hyperlipidemia Based on Network Pharmacology and Experimental Validation. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-23.
Crossref
Crossref
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
133
198
.
Gagan D. Flora & Manasa K. Nayak. (2019) A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes. Current Pharmaceutical Design 25:38, pages 4063-4084.
Crossref
Crossref
Jiang Wu, Qunchao Zhao, Thomas C. Wilson, Stefan Verhoog, Long Lu, Véronique Gouverneur & Qilong Shen. (2019)
Synthesis and Reactivity of α‐Cumyl Bromodifluoromethanesulfenate: Application to the Radiosynthesis of [
18
F]ArylSCF
3
. Angewandte Chemie International Edition 58:8, pages 2413-2417.
Crossref
Crossref
Jiang Wu, Qunchao Zhao, Thomas C. Wilson, Stefan Verhoog, Long Lu, Véronique Gouverneur & Qilong Shen. (2019)
Synthesis and Reactivity of α‐Cumyl Bromodifluoromethanesulfenate: Application to the Radiosynthesis of [
18
F]ArylSCF
3
. Angewandte Chemie 131:8, pages 2435-2439.
Crossref
Crossref
Ziyad S. Almalki, Jeff Jianfei Guo, Abdullah Alahmari, Nawaf Alotaibi & Hilal Thaibah. (2018) Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. Heart, Lung and Circulation 27:6, pages 656-665.
Crossref
Crossref
Viruna Neergheen, Alex Dyson, Luke Wainwright & Iain P. Hargreaves. 2018. Mitochondrial Dysfunction Caused by Drugs and Environmental Toxicants. Mitochondrial Dysfunction Caused by Drugs and Environmental Toxicants
457
473
.
Vasilios G. Athyros, Michael Doumas, Konstantinos P. Imprialos, Konstantinos Stavropoulos, Eleni Georgianou, Alexandra Katsimardou & Asterios Karagiannis. (2018) Diabetes and lipid metabolism. Hormones 17:1, pages 61-67.
Crossref
Crossref
Dennie G. A. J. Hebels, Axel Rasche, Ralf Herwig, Gerard J. P. van Westen, Danyel G. J. Jennen & Jos C. S. Kleinjans. 2016. In Silico Methods for Predicting Drug Toxicity. In Silico Methods for Predicting Drug Toxicity
339
359
.
C. Roger White, Dennis I. Goldberg & G.M. Anantharamaiah. (2015) Recent developments in modulating atherogenic lipoproteins. Current Opinion in Lipidology 26:5, pages 369-375.
Crossref
Crossref
Min Jun & Vlado Perkovic. 2015. Dyslipidemias. Dyslipidemias
423
438
.
C. Roger White, David W. Garber & G.M. Anantharamaiah. (2014) Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review. Journal of Lipid Research 55:10, pages 2007-2021.
Crossref
Crossref
Jaspinder Kaur. (2014) A Comprehensive Review on Metabolic Syndrome. Cardiology Research and Practice 2014, pages 1-21.
Crossref
Crossref
Bela F. Asztalos, Mariko Tani & Brian Ishida. 2014. The HDL Handbook. The HDL Handbook
37
64
.
Natalia Andrushko & Vasyl Andrushko. 2015. Stereoselective Synthesis of Drugs and Natural Products. Stereoselective Synthesis of Drugs and Natural Products
1
52
.
Natalia Andrushko & Vasyl Andrushko. 2013. Stereoselective Synthesis of Drugs and Natural Products. Stereoselective Synthesis of Drugs and Natural Products
1
50
.
A. E. Bochem, D. F. van Wijk, A. G. Holleboom, R. Duivenvoorden, M. M. Motazacker, G. M. Dallinga-Thie, E. de Groot, J. J. P. Kastelein, A. J. Nederveen, G. K. Hovingh & E. S. G. Stroes. (2012) ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. European Heart Journal 34:4, pages 286-291.
Crossref
Crossref
Yurong Lai. 2013. Transporters in Drug Discovery and Development. Transporters in Drug Discovery and Development
353
454
.
J.J. Scarisbrick, S. Morris, R. Azurdia, T. Illidge, E. Parry, R. Graham-Brown, R. Cowan, E. Gallop-Evans, R. Wachsmuth, M. Eagle, A.S. Wierzbicki, H. Soran, S. Whittaker & E.M. Wain. (2013) U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. British Journal of Dermatology 168:1, pages 192-200.
Crossref
Crossref
Adie Viljoen & Anthony S. Wierzbicki. 2012. Cardiovascular Disease and Health in the Older Patient. Cardiovascular Disease and Health in the Older Patient
68
89
.
H. Kamp, V. Strauss, J. Wiemer, E. Leibold, T. Walk, W. Mellert, R. Looser, A. Prokoudine, E. Fabian, G. Krennrich, M. Herold & B. van Ravenzwaay. (2012) Reproducibility and robustness of metabolome analysis in rat plasma of 28-day repeated dose toxicity studies. Toxicology Letters 215:2, pages 143-149.
Crossref
Crossref
V. Strauss, W. Mellert, J. Wiemer, E. Leibold, H. Kamp, T. Walk, R. Looser, A. Prokoudine, E. Fabian, G. Krennrich, M. Herold & B. van Ravenzwaay. (2012) Increased toxicity when fibrates and statins are administered in combination – A metabolomics approach with rats. Toxicology Letters 211:2, pages 187-200.
Crossref
Crossref
I. Kouroumichakis, N. Papanas, P. Zarogoulidis, V. Liakopoulos, E. Maltezos & D.P. Mikhailidis. (2012) Fibrates: Therapeutic potential for diabetic nephropathy?. European Journal of Internal Medicine 23:4, pages 309-316.
Crossref
Crossref
Adie Viljoen & Anthony S. Wierzbicki. 2012. Pathy's Principles and Practice of Geriatric Medicine. Pathy's Principles and Practice of Geriatric Medicine
449
460
.
Luis Rodríguez Padial & Francisco Ridocci Soriano. (2012) Eficacia bioquímica y beneficio clínico de la doble inhibición con ezetimiba y simvastatina. Revista Española de Cardiología Suplementos 12, pages 2-7.
Crossref
Crossref
Cesare Indiveri, Vito Iacobazzi, Annamaria Tonazzi, Nicola Giangregorio, Vittoria Infantino, Paolo Convertini, Lara Console & Ferdinando Palmieri. (2011) The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathology. Molecular Aspects of Medicine 32:4-6, pages 223-233.
Crossref
Crossref
A. P. Agouridis, V. Tsimihodimos, T. D. Filippatos, A. D. Tselepis & M. S. Elisaf. (2011) High Doses of Rosuvastatin are Superior to Low Doses of Rosuvastatin Plus Fenofibrate or n‐3 Fatty Acids in Mixed Dyslipidemia. Lipids 46:6, pages 521-528.
Crossref
Crossref
A. Viljoen. (2011) A practical approach to lipid management in the elderly. The journal of nutrition, health & aging 15:1, pages 65-70.
Crossref
Crossref
Adie Viljoen. (2010) A practical approach to lipid management in the elderly. The journal of nutrition, health & aging.
Crossref
Crossref
Anthony S Wierzbicki. (2010) Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Current Opinion in Lipidology 21:4, pages 352-358.
Crossref
Crossref
M. John Chapman, Jan S. Redfern, Mark E. McGovern & Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, pages 314-345.
Crossref
Crossref
Andrea O. Luk, Xilin Yang, Ronald C. Ma, Vanessa W. Ng, Linda W. Yu, Winnie W. Lau, Risa Ozaki, Francis C. Chow, Alice P. Kong, Peter C. Tong, Juliana C. Chan & Wingyee So. (2010) Association of statin use and development of renal dysfunction in type 2 diabetes—The Hong Kong Diabetes Registry. Diabetes Research and Clinical Practice 88:3, pages 227-233.
Crossref
Crossref
Natalia Andrushko, Vasyl Andrushko, Vitali Tararov, Andrei Korostylev, Gerd König & Armin Börner. (2010) Highly stereoselective hydrogenations-As key-steps in the total synthesis of statins. Chirality 22:5, pages 534-541.
Crossref
Crossref
Asuka Maeda, Takahisa Yano, Yoshinori Itoh, Midori Kakumori, Toshio Kubota, Nobuaki Egashira & Ryozo Oishi. (2010) Down-regulation of RhoA is involved in the cytotoxic action of lipophilic statins in HepG2 cells. Atherosclerosis 208:1, pages 112-118.
Crossref
Crossref
Vito Iacobazzi, Paolo Convertini, Vittoria Infantino, Pasquale Scarcia, Simona Todisco & Ferdinando Palmieri. (2009) Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression. Biochemical and Biophysical Research Communications 388:4, pages 643-647.
Crossref
Crossref
Anthony S Wierzbicki. (2009) Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Current Opinion in Cardiology 24:4, pages 372-379.
Crossref
Crossref
A. S. Wierzbicki. (2009) Interpreting clinical trials of diabetic dyslipidaemia: new insights. Diabetes, Obesity and Metabolism 11:3, pages 261-270.
Crossref
Crossref
Muzaffer Sapan, Beste Ozben, Gulsen Yakupoglu, Gultekin SuleymanlarTomris Ozben. (2023) Effects of Diet and Gemfibrozil on Posttransplant Hyperlipidemia in Renal Transplant Recipients. Journal of Investigative Medicine 57:2, pages 456-459.
Crossref
Crossref
Rohit Seth Loomba & Rohit Arora. (2009) Fibrates: where are we now?. Therapeutic Advances in Cardiovascular Disease 3:1, pages 91-96.
Crossref
Crossref
V. G. Athyros, A. I. Kakafika, A. S. Wierzbicki, A. Karagiannis & D. P. Mikhailidis. (2009) Targeting triglycerides in secondary prevention: should we bother?. International Journal of Clinical Practice 63:1, pages 15-18.
Crossref
Crossref
C. Roger White, Geeta Datta, Zhenghao Zhang, Himanshu Gupta, David W. Garber, Vinod K. Mishra, Mayakonda N. Palgunachari, Shaila P. Handattu, Manjula Chaddha & G. M. Anantharamaiah. (2008) HDL therapy for cardiovascular diseases: the road to HDL mimetics. Current Atherosclerosis Reports 10:5, pages 405-412.
Crossref
Crossref
Peter Collins. (2008) HDL-C in post-menopausal women: An important therapeutic target. International Journal of Cardiology 124:3, pages 275-282.
Crossref
Crossref
Helene GlassbergDaniel J. Rader. (2008) Management of Lipids in the Prevention of Cardiovascular Events. Annual Review of Medicine 59:1, pages 79-94.
Crossref
Crossref
Peter H Jones, Harold E Bays, Michael H Davidson, Maureen T Kelly, Susan M Buttler, Carolyn M Setze, Darryl J Sleep & James C Stolzenbach. (2008) Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins. Clinical Drug Investigation 28:10, pages 625-634.
Crossref
Crossref
Juan Pedro-Botet. (2008) Review: The role of fenofibrate in reducing cardiovascular risk in type 2 diabetes. The British Journal of Diabetes & Vascular Disease 8:1, pages 22-27.
Crossref
Crossref
Dimitri P. Mikhailidis. 2008. Vascular Complications in Human Disease. Vascular Complications in Human Disease
179
186
.
J. Shepherd. (2007) Dyslipidaemia in diabetic patients: time for a rethink. Diabetes, Obesity and Metabolism 9:5, pages 609-616.
Crossref
Crossref
Paul Durrington. 2007. Hyperlipidaemia 3Ed. Hyperlipidaemia 3Ed
258
291
.
Deoraj Zamvar & Alistair Hall. 2007. Heart Disease and the Surgical Patient. Heart Disease and the Surgical Patient
349
370
.
Anthony S Wierzbicki. (2016) Fibrates after the FIELD study: some answers, more questions. Diabetes and Vascular Disease Research 3:3, pages 166-171.
Crossref
Crossref
Hamad S. Al-Barjas, Robert Ariëns, Peter Grant & Julian A. Scott. (2016) Raised Plasma Fibrinogen Concentration in Patients With Abdominal Aortic Aneurysm. Angiology 57:5, pages 607-614.
Crossref
Crossref
Terje R Pedersen, Gerd Assmann, Jean-Pierre Bassand, M John Chapman, Raimund Erbel & Cesare Sirtori. (2016) Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. Diabetes and Vascular Disease Research 3:2_suppl, pages S1-S12.
Crossref
Crossref
G. I. VARUGHESE & J. H. B. SCARPELLO. (2008) Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: a less commonly perceived therapeutic perspective in clinical practice. International Journal of Clinical Practice 60:7, pages 884-888.
Crossref
Crossref
A. Rees. (2006) FIELD study. Diabetic Medicine 23:s3, pages 6-12.
Crossref
Crossref
Andrea Cignarella, Stefano Bellosta, Alberto Corsini & Chiara Bolego. (2006) Hypolipidemic therapy for the metabolic syndrome. Pharmacological Research 53:6, pages 492-500.
Crossref
Crossref
A. S. Wierzbicki. (2006) FIELDS of dreams, fields of tears: a perspective on the fibrate trials. International Journal of Clinical Practice 60:4, pages 442-449.
Crossref
Crossref
Rasha YA Mukhtar & John PD Reckless. (2006) Statin-induced myositis: a commonly encountered or rare side effect?. Current Opinion in Internal Medicine 5:1, pages 34-41.
Crossref
Crossref
Hiroyasu Naba, Chihaya Kakinuma, Shuhei Ohnishi & Takuo Ogihara. (2006) Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats. Biochemical and Biophysical Research Communications 340:1, pages 215-220.
Crossref
Crossref
M John Chapman. (2016) Review: Fibrates: therapeutic review. The British Journal of Diabetes & Vascular Disease 6:1, pages 11-19.
Crossref
Crossref
Luis Rodríguez Padial, Juan Alcalá López & Elena Refoyo Salicio. (2006) Beneficios de la terapia combinada en la hiperlipemia. Revista Española de Cardiología Suplementos 6:7, pages 63G-71G.
Crossref
Crossref
Michael Schachter. (2006) Strategies for Modifying High-Density Lipoprotein Cholesterol: A Role for Nicotinic Acid. Cardiovascular Drugs and Therapy 19:6, pages 415-422.
Crossref
Crossref
Alberto Corsini, Stefano Bellosta & Michael H. Davidson. (2005) Pharmacokinetic Interactions Between Statins and Fibrates. The American Journal of Cardiology 96:9, pages 44-49.
Crossref
Crossref
Richard A. Krasuski, Dennis Doeppenschmidt, John S. Henry, P. Brad Smith, Joseph Adinaro, Rachel Beck & Christopher M. Thompson. (2005) Conversion to Atorvastatin in Patients Intolerant or Refractory to Simvastatin Therapy: The CAPISH Study. Mayo Clinic Proceedings 80:9, pages 1163-1168.
Crossref
Crossref
Kosmas I. ParaskevasStella S. Daskalopoulou, Marios E. Daskalopoulos & Christos D. Liapis. (2016) Secondary Prevention of Ischemic Cerebrovascular Disease. What Is the Evidence?. Angiology 56:5, pages 539-552.
Crossref
Crossref
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Triandafillos P. Didangelos, Athanasia Peletidou, Drosia Kleta, Asterios Karagiannis, Anna I. Kakafika, Konstantinos Tziomalos & Moses Elisaf. (2005) Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 54:8, pages 1065-1074.
Crossref
Crossref
G D Kolovou, K K Anagnostopoulou & D V Cokkinos. (2005) Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgraduate Medical Journal 81:956, pages 358-366.
Crossref
Crossref
Michel Farnier, Mason W. Freeman, Geraldine Macdonell, Inna Perevozskaya, Michael J. Davies, Yale B. Mitchel & Barry Gumbiner. (2005) Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. European Heart Journal 26:9, pages 897-905.
Crossref
Crossref
Roberto Pedrinelli, Ezio Degli Esposti & Giulia Dell’Omo. (2005) LDL cholesterol and global risk stratification in referred hypertensive patients. Atherosclerosis 180:1, pages 137-143.
Crossref
Crossref
Conrad P Earnest, Alexander N Jordan, Melinda Safir, Eric Weaver & Timothy S Church. (2005) Cholesterol-lowering effects of bovine serum immunoglobulin in participants with mild hypercholesterolemia. The American Journal of Clinical Nutrition 81:4, pages 792-798.
Crossref
Crossref
Nikolaos P. KadoglouStella S. Daskalopoulou, Despina Perrea & Christos D. Liapis. (2016) Matrix Metalloproteinases and Diabetic Vascular Complications. Angiology 56:2, pages 173-189.
Crossref
Crossref
G.D. Kolovou, K.K. Anagnostopoulou, N.D. Pilatis, S. Iraklianou, I.S. Hoursalas, S. Liberi, A.N. Pavlidis, A. Dritsas, D.P. Mikhailidis & D.V. Cokkinos. (2004) Heterozygote men with familial hypercholesterolaemia may have an abnormal triglyceride response post-prandially. Evidence for another predictor of vascular risk in familial hypercholesterolaemia. International Journal of Clinical Practice 59:3, pages 311-317.
Crossref
Crossref
S. Wijeratne, R. Wray, P.O. Collinson & A.S. Wierzbicki. (2005) Hypertriglyceridaemia and malignancy. International Journal of Clinical Practice 59:2, pages 253-255.
Crossref
Crossref
Marilda Mazzali. (2005) Uric acid and transplantation. Seminars in Nephrology 25:1, pages 50-55.
Crossref
Crossref
S. S. Daskalopoulou, D. P. Mikhailidis & M. Elisaf. (2016) Prevention and Treatment of the Metabolic Syndrome. Angiology 55:6, pages 589-612.
Crossref
Crossref
A.S. Wierzbicki. (2004) Lipid-altering agents: the future. International Journal of Clinical Practice 58:11, pages 1063-1072.
Crossref
Crossref
Emma A. Meagher. (2004) Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story. Current Cardiology Reports 6:6, pages 457-463.
Crossref
Crossref
Yoshihisa Shitara, Masaru Hirano, Hitoshi Sato & Yuichi Sugiyama. (2004)
Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:
SLC21A6
)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil
. Journal of Pharmacology and Experimental Therapeutics 311:1, pages 228-236.
Crossref
Crossref
G. De Angelis. (2004) The influence of statin characteristics on their safety and tolerability. International Journal of Clinical Practice 58:10, pages 945-955.
Crossref
Crossref
Richard L. Dunbar & Daniel J. Rader. (2004) Therapeutic strategies for the treatment of dyslipidemia. Drug Discovery Today: Therapeutic Strategies 1:2, pages 169-176.
Crossref
Crossref
Anthony S. Wierzbicki. (2004) Raising high-density lipoprotein. International Journal of Clinical Practice 58:9, pages 817-819.
Crossref
Crossref
Nick Plant. (2004) Interaction networks: coordinating responses to xenobiotic exposure. Toxicology 202:1-2, pages 21-32.
Crossref
Crossref
H. Schuster. (2004) Improving lipid management - to titrate, combine or switch. International Journal of Clinical Practice 58:7, pages 689-694.
Crossref
Crossref
Alessandra Picollo, Antonella Liantonio, Maria Paola Didonna, Laura Elia, Diana Conte Camerino & Michael Pusch. (2004) Molecular determinants of differential pore blocking of kidney CLC‐K chloride channels. EMBO reports 5:6, pages 584-589.
Crossref
Crossref
Herbert Schuster. (2004) Risk assessment and strategies to achieve lipid goals: lessons from real-world clinical practice. The American Journal of Medicine 116:6, pages 26-30.
Crossref
Crossref
Anthony S Wierzbicki, Robin Poston & Albert Ferro. (2003) The lipid and non-lipid effects of statins. Pharmacology & Therapeutics 99:1, pages 95-112.
Crossref
Crossref